EUVIMEDEUVIMED entdecken
Open Access

Raising NAD + Level Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation

Matthew A Walker iD, Hongye Chen iD, Aprajita Yadav iD, Julia Ritterhoff iD, Outi Villet, Tim McMillen, Yuliang Wang, Hayley Purcell, Danijel Djukovic, Daniel Raftery iD, Nina Isoherranen iD, Rong Tian iD

Circulation · 19.12.2023 · 148 (25) · 2038-2057

DOI: 10.1161/circulationaha.123.066039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 19.12.2023. Verfasst von Matthew A Walker und 11 weiteren Autor:innen. Beteiligte Einrichtung: Mitochondria and Metabolism Center, Department of Anesthesiology & Pain Medicine (M.A.W., H.C., J.R., O.V., T.M., H.P., D.D., D.R., R.T.), University…. Hauptthemen laut MEDLINE: Sirtuin 3, Heart Failure, Heart Diseases. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Strategies to increase cellular NAD + (oxidized nicotinamide adenine dinucleotide) level have prevented cardiac dysfunction in multiple models of heart failure, but molecular mechanisms remain unclear. Little is known about the benefits of NAD + -based therapies in failing hearts after the symptoms of heart failure have appeared. Most pretreatment regimens suggested mechanisms involving activation of sirtuin, especially Sirt3 (sirtuin 3), and mitochondrial protein acetylation. METHODS: We induced cardiac dysfunction by pressure overload in SIRT3-deficient (knockout) mice and compared their response with nicotinamide riboside chloride treatment with wild-type mice. To model a therapeutic approach, we initiated the treatment in mice with established cardiac dysfunction. RESULTS: We found nicotinamide riboside chloride improved mitochondrial function and blunted heart failure progression. Similar benefits were observed in wild-type and knockout mice. Boosting NAD + level improved the function of NAD(H) redox-sensitive SDR (short-chain dehydrogenase/reductase) family proteins. Upregulation of Mrpp2 (mitochondrial ribonuclease P protein 2), a multifunctional SDR protein and a subunit of mitochondrial ribonuclease P, improves mitochondrial DNA transcripts processing and electron transport chain function. Activation of SDRs in the retinol metabolism pathway stimulates RXRα (retinoid X receptor α)/PPARα (proliferator-activated receptor α) signaling and restores mitochondrial oxidative metabolism. Downregulation of Mrpp2 and impaired mitochondrial ribonuclease P were found in human failing hearts, suggesting a shared mechanism of defective mitochondrial biogenesis in mouse and human heart failure. CONCLUSIONS: These findings identify SDR proteins as important regulators of mitochondrial function and molecular targets of NAD + -based therapy. Furthermore, the benefit is observed regardless of Sirt3-mediated mitochondrial protein deacetylation, a widely held mechanism for NAD + -based therapy for heart failure. The data also show that NAD + -based therapy can be useful in pre-existing heart failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sirtuin 3Heart FailureHeart DiseasesMiceHumansAnimalsMitochondrial ProteinsNADRibonuclease PChloridesMitochondriaMice, KnockoutOxidoreductases

Stichwörter der Autor:innen

NAD+heart failuremitochondrianicotinamide ribosideshort-chain dehydrogenasesirtuin

Substanzen

Mitochondrial ProteinsNADSirtuin 3Ribonuclease PChloridesOxidoreductases

Autor:innen und Institutionen

  • Mitochondria and Metabolism Center, Department of Anesthesiology & Pain Medicine (M.A.W., H.C., J.R., O.V., T.M., H.P., D.D., D.R., R.T.), University of Washington, Seattle.
  • Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China (H.C.).
  • Department of Pharmaceutics, School of Pharmacy (A.V., N. I.), University of Washington, Seattle.
  • Department of Computer Science & Engineering (Y.W.), University of Washington, Seattle.

ORCID-Profile: Matthew A Walker, Hongye Chen, Aprajita Yadav, Julia Ritterhoff, Daniel Raftery, Nina Isoherranen, Rong Tian

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • American Heart Association-American Stroke Association

Zitieren

APA

Walker, M. A., Chen, H., Yadav, A., Ritterhoff, J., Villet, O., McMillen, T., Wang, Y., Purcell, H., Djukovic, D., Raftery, D., Isoherranen, N., & Tian, R. (2023). Raising NAD + Level Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation. Circulation, 148(25), 2038-2057. https://doi.org/10.1161/circulationaha.123.066039

Vancouver

Walker MA, Chen H, Yadav A, Ritterhoff J, Villet O, McMillen T, et al. Raising NAD + Level Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation. Circulation. 2023;148(25):2038-2057. doi:10.1161/circulationaha.123.066039

BibTeX
@article{Walker2023,
  author = {Walker, Matthew A and Chen, Hongye and Yadav, Aprajita and Ritterhoff, Julia and Villet, Outi and McMillen, Tim and Wang, Yuliang and Purcell, Hayley and Djukovic, Danijel and Raftery, Daniel and Isoherranen, Nina and Tian, Rong},
  title = {Raising NAD + Level Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation},
  journal = {Circulation},
  year = {2023},
  volume = {148},
  number = {25},
  pages = {2038--2057},
  doi = {10.1161/circulationaha.123.066039}
}
Kostenlos starten →